Metabolic disorders

The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech history; ObesityWeek and Clinical Trials on Alzheimer’s Disease conferences in full swing.
As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed investors a couple of years ago.
Across three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw said following the company’s ObesityWeek update.
ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persistence on treatment.
With 10 active or planned Phase 3 trials underway for Metsera’s berobenatide, Pfizer has signed a deal with Blackstone Life Sciences to finance the program to approval.
Novartis confirms that nine patients treated with its spinal muscular atrophy gene therapy Zolgensma have developed tumors; the FDA orders GLP-1 drugmakers to add a warning to their labels about the risk of a rare eye condition that can lead to vision loss; and the agency is set to decide on no fewer than 11 therapies this month, including closely watched applications from Summit Therapeutics, Vertex and Capricor Therapeutics.
Twelve marketed drugs, including Eli Lilly’s and Novo’s weight loss mega-blockbusters, will require a label change under the new FDA update.
The Phase 3 results help clarify the safety profile of Zealand and Boehringer Ingelheim’s survodutide, but analysts do not think the drug will find utility beyond patients with liver-related risk factors.
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not be the last for the hot ticket metabolic biotech.
To build on the momentum in MASH, we—at Madrigal Pharmaceuticals and the industry more widely—must further expand approaches to diagnosis, monitoring and individualized treatment to help more patients.
PRESS RELEASES